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Abstract
Background: The diagnosis of smear-negative or sputum-scarce tuberculosis (TB) is problematic as culture takes several
weeks and representative biological samples are difficult to obtain. RD-1 antigen-specific interferon-c release assays (IGRAs)
are sensitive and specific blood-based tests for the diagnosis of M. tuberculosis infection. The feasibility and diagnostic utility
of this rapid immunodiagnostic assay, using cells from induced sputum, is unknown.
Methodology/Principal Findings: Cells isolated from induced sputum were co-cultured with ESAT-6 and CFP-10 antigens
using a standardized enzyme-linked immunospot (ELISPOT) assay (T-SPOTH.TB) in 101 consecutively recruited TB suspects or
non-TB controls. An optimization phase using 28 samples was followed by a validation phase using samples from 73
participants (20 with definite or probable TB, and 48 with non-TB). Despite optimization of sputum processing 65/73 (89%)
of the IGRAs in the validation phase were inconclusive. 44/73 (60%) tests failed due to sputum induction-related factors
[sputum induction-related adverse events (n = 5), inadequate sputum volume (n = 8), non-homogenisable sputum (n = 7),
and insufficient numbers of cells to perform the assay (n = 24)], whilst 20/73 (27%) tests failed due T-SPOTH.TB assay-related
factors [excessive debris precluding reading of spots in the ELISPOT well (n = 6), failure of the positive control (n = 11), or
high spot count in the negative control (n = 3)]. Only 8/73 (11%) of the available samples could therefore be correctly
categorized (7 definite or probable TB, and 1 non-TB patient). Thus, 13/20 (65%) of the definite or probable TB cases
remained undiagnosed.
Conclusions/Significance: Rapid immunodiagnosis of pulmonary TB by antigen-specific IFN-c ELISPOT responses, using
cells from induced sputum, is possible. However, the test, in its current ELISPOT format, is not clinically useful because the
majority of the assays are inconclusive.
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Introduction
Tuberculosis (TB) has become a public health catastrophe in the
developing world. The most recent WHO figures estimate a
worldwide TB incidence of 9.27 million per year and 1.8 million
deaths annually [1]. TB control efforts are hampered by
suboptimal diagnostic tools and techniques. The sensitivity of
routine smear-microscopy is approximately 50% [2], culture
techniques take several weeks to yield results, and suitable
representative biological samples are frequently unobtainable
either due to lack of sputum production or poor sample quality.
The HIV pandemic compounds this problem by increasing the
incidence of smear-negative and sputum-scare TB [3].
Alternative techniques to obtain pulmonary samples are
required in these patients including sputum induction (SI), gastric
washings and bronchoscopy [4,5]. However, bronchoscopy is
expensive, invasive and not widely available in resource-limited
settings, while gastric washing is largely limited to use in children.
In contrast, sputum induction is non-invasive, less costly, has fewer
side effects and has been shown to provide an equal, or higher
microbiological yield when compared to bronchoscopy [6,7,8]. In
resource-limited settings, therefore, the use of sputum induction
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could provide an ideal patient-friendly option. Nevertheless, rapid
diagnosis of Mycobacterium tuberculosis (M.tb) is still frequently
impossible given the low yield of smear microscopy, approximately
7–32% in this context [9,10].
More recently the interferon-c release assays (IGRAs) based on
peripheral blood mononuclear responses to M.tb region of
difference-1 (RD-1)-specific antigens [early secretory antigenic
target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10)], have
been shown to be highly sensitive and specific tests for the
diagnosis of M.tb infection [11,12]. In addition, the standardised
RD-1 ELISPOT assay (T-SPOTH.TB) has also shown to be an
accurate tool for the rapid diagnosis of active TB using
cerebrospinal fluid mononuclear cells [13], and broncho-alveolar
lavage cells [14,15]. Thus, the ELISPOT assay can be accurately
used to diagnose active TB using cells from the site of disease.
We hypothesized that performing an IGRA, using mononuclear
cells from induced sputum, could enable rapid immunodiagnosis
of TB in a more patient-friendly and cost-effective manner. The
feasibility and diagnostic utility of this approach using RD-1
antigen-specific ELISPOT responses has hitherto not been
evaluated.
Materials and Methods
Clinical recruitment
Eighty-one adults with suspected TB and twenty non-TB
controls (8 with COPD or asthma, 6 with interstitial lung disease, 2
with cystic fibrosis, 2 with bronchiectasis, and 2 with lung cancer)
were recruited from primary health care clinics in suburban Cape
Town, and the Respiratory Clinic at Groote Schuur Hospital,
South Africa between March 2008 and March 2010. (Figure 1) All
patients had a chest x-ray and sputum induction performed.
Standard short course anti-TB therapy was administered, when
appropriate, according to local guidelines.
Ethical approval was obtained from the University of Cape
Town’s Health Science Faculty Research Ethics Committee (REC
number 421/2006). Each patient gave written informed consent
prior to participation in the study.
Sample acquisition and processing
Sputum induction. All participants were requested to rinse
their mouths with water and then be seated in an enclosed
negative-pressure sputum induction booth. Approximately 20 ml
of sterile 5% hypertonic saline (Sabax, Adcock Ingram Critical
Care (PTY) LTD, Johannesburg, South Africa) was delivered via a
Wilson’s 402A ultrasonic nebuliser (Medimark, South Africa) over
a period of 15 minutes or until 4–12 ml of induced sputum could
be collected in a sterile container. No pro-expectorating
maneuvers, such as chest percussion, were employed. Induction
was immediately terminated if side effects such as dyspnoea, chest
discomfort or nausea were reported. Strict infection control
measures were followed during sample acquisition and
processing. To avoid confounding, the same technician
performed all laboratory assays and was blinded to the patient’s
final diagnosis.
Optimisation of the ELISPOT assay using cells from
induced sputum. Given the lack of established processing
methods, using induced sputum cells in an ELISPOT assay, an
optimization phase using 28 patient samples was undertaken (see
figure 1). To determine the optimal method for sputum
homogenization different volumes of 0.1% dithiothreitrol (DTT)
(Sigma, UK) were added to sputum samples, and the volume and
rolling time determined by the sample’s final macroscopic
appearance, viability of the induced sputum mononuclear cells
(trypan blue method), and the degree of background discoloration
in the ELISPOT well. In summary, a 2:1 volume ratio of 0.1%
DTT to induced sputum with a rolling time of 20 minutes was
sufficient to digest all mucins with minimal cell death and
background well discoloration of the assays.
After homogenization and cell counting (Neubauer Haemacy-
tometer) the sample was filtered either through 2-ply sterile gauze
[22% (range 0–54%) loss of mononuclear cells], a 100 mm cell
strainer [56% (range 17–100%) cell loss]or using a ficoll density
gradient centrifugation [93% (range 85–99%) cell loss]. Thus,
using sterile gauze was determined to be the optimal filtration
method.
To determine the optimal number of cells to be used per
ELISPOT well, mononuclear induced sputum cells from 3 smear-
positive subjects with TB were plated in duplicate wells at several
concentrations. 250 000 cells/well was determined to be the
optimal cell number to be used per well with a further increase in
cell number per well diminishing antigen-specific responses
(Figure 2).
Sample processing for validation phase. Seventy-three
patients were included in the validation phase (Figure 1). Samples
were processed according to methods derived from the
optimization phase (dilution with 0.1% DTT twice the sputum
volume, homogenization and rolling for 20 minutes at room
temperature, and filtration through 2-ply sterile gauze). A 2–6 ml
aliquot was removed and sent for microbiological testing. The
sample was then washed twice with BioWhittakerH 10%
phosphate buffered saline (Lonza, Walkersville, USA) and cells
isolated by centrifugation at 3006g for 10 minutes. Mononuclear
cells were resuspended in 1–2 ml AIM-VH medium (Gibco,
Invitrogen) counted, viability assessed and plated in duplicate in
the ELISPOT assay.
Enumeration of RD-1 specific T cells
The T-SPOTH.TB assay was performed as per the manufac-
turer’s instructions. Spot forming units/106 cells (SFUs), repre-
senting IFN-c release by peptide-specific T cells, were counted
with an automated AID-ELISPOT reader system (Autoimmun
Diagnostika, Strassberg, Germany), and confirmed by manual
counting. The diagnosis of TB was based on the number of SFUs
according to the manufacturer’s guidelines for peripheral blood
mononuclear cells.
Diagnostic classification
Smear-microscopy was performed on centrifuged and processed
sputum using fluorescence microscopy, and sputum quality was
assessed using Gram staining. The following criteria were used for
final diagnostic classification:
(i) Definite TB – positive culture for M. tuberculosis (MGIT 960
platform).
(ii) Probable TB – TB highly likely and the patient treated for
TB on clinical or radiological grounds, but in the absence of
a confirmed microbiological diagnosis.
(iii) Non-TB – smear microscopy and culture negative, no chest
x-ray evidence of active TB, and not treated for tuberculosis,
or successful treatment for an alternative infection. The
subject remained healthy at follow-up (6 months).
Data analyses
Statistical analysis was performed using STATA version 8.
GraphPad Prism (version 4.0 or higher) was used for graphs and
figures.
Sputum ELISPOT TB Diagnosis
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Results
Patient demographics & clinical characteristics
The demographic characteristics of the seventy three subjects
included in the validation phase are shown in table 1. The HIV
prevalence was 29%. Sixteen (23%) patients had definite TB, 4
(6%) probable TB and 48 (71%) non-TB. There were no
significant differences between the definite and non-TB groups.
Sputum induction and processing
The median duration of sputum induction was 15 minutes
(range: 5–20 minutes). Periods of less than 15 minutes were
deemed acceptable if a suitable sample was obtained. Five (6%) of
Figure 1. Study flow diagram. Study plan and patient categorisation of the 28 and 73 participants evaluated in the optimization and validation
phases, respectively.
doi:10.1371/journal.pone.0010389.g001
Figure 2. Optimization of mononuclear sputum cell number.
Trend lines represent mean numbers of spots in ESAT-6-stimulated
wells using cells from smear-positive individuals. All positive and
negative controls were valid.
doi:10.1371/journal.pone.0010389.g002
Table 1. Demographic information of patients included in
the validation phase excluding 5 patients who were
un-inducible.
Total Definite TB Probable TB Non-TB
Number of
subjects
68 16(23%) 4 (6%) 48 (71%)
Age mean(SD) 46 (17) 38 (15) 48 (10) 49 (17)
Sex
Male 33(49%) 10(63%) 3(75%) 20(42%)
Racial group
Black African 29(43%) 9 (56%) 3(75%) 17(35%)
Mixed Ancestry 35(51%) 7 (44%) 1(25%) 27(56%)
European Ancestry 4(6%) 0 0 4(9%)
Current smoker 20 (29%) 5 (31%) 2(50%) 13(27%)
HIV status
positive 20 (29%) 7 (44%) 3(75%) 10 (21%)
unknown/refused
testing
10 (15%) 0 0 10 (21%)
Previous TB
(n=54)
16(24%) 5(31%) 2(50%) 9(19%)
doi:10.1371/journal.pone.0010389.t001
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the total 73 sputum inductions were prematurely terminated
(nausea and/or vomiting in 2 patients and chest pain in 3 patients).
The median volume of induced sputum was 7 ml (range: 4–12 ml)
while 8 patients produced #1 ml which was considered inade-
quate for further processing (a summary of test outcomes and
reasons for un-evaluable results is presented in Table 2). Due to
the presence of large mucus plugs 7 samples could not be
successfully homogenised, and thus could not be adequately
filtered. Amongst samples successfully homogenised, filtered and
washed the median (range) sputum cell concentration (cells/
milliliter sputum) was 0.16106 cells/ml (0–2.46106), and the
viability greater than 90%. The differential cell counts showed a
median (range) lymphocyte count of 21% (0–75%) and neutrophil
count of 79% (10–95%). Scanty macrophages were occasionally
detected. Female patients produced significantly less sputum
volumes and consequently sputum cell concentrations (p = 0.027
and p= 0.038, respectively). There was no correlation between
induced sputum volumes, cell concentrations or age, and HIV
status. Total sputum cell numbers were highly variable and in 23
patients there was insufficient cells to perform the T-SPOTH.TB
assay (Table 2) while in a further 19 cases the samples’ total cell
yields were insufficient to plate the optimal 250 000 cells/well, and
consequently these assays we performed using concentrations
above 100 000 cells/well.
ELISPOT assay
Of the 73 patients included in the validation phase, after
processing only 29 samples had a sufficient total cell number to
warrant performing the T-SPOTH.TB assay (Table 2). Only eight
of these 29 samples produced evaluable T-SPOTH.TB results. The
main reasons for unevaluable T-SPOTH.TB assay results are
outlined in table 2 and photographic examples are shown in
Figure 3A–F.
Thus, overall only 8/73 (11%) of the samples collected yielded
an evaluable T-SPOTH.TB result. Of these 7 were positive with a
median(IQR) of 96(21,164) SFUs for the ESAT-6 and 64 (0,250)
CFP-10 wells, respectively. All 7 positive samples were from TB
patients and the one negative sample was from a non TB patient.
The relationship between evaluable T-SPOTH.TB results and
AFB smear and culture results are illustrated in table 3.
Discussion
We evaluated the diagnostic utility of induced sputum mononu-
clear cells in the RD-1 ELISPOT assay as a rapid immunodiag-
nostic test for active tuberculosis. However, only 8/73 (11%)
collected samples yielded evaluable test results. Nevertheless, despite
the major technical difficulties and frequent invalid results, the assay
was highly sensitive in the limited number of evaluable results. Our
study, using a standardized ELISPOT assay incorporating RD-1
specific antigens (ESAT-6 and CFP-10), confirms that rapid
immunodiagnosis of M.tb infection is indeed possible using
mononuclear cells from induced sputum, but demonstrates that
due to technical factors its clinical utility is limited.
In contrast to our findings Breen et al. demonstrated, in a limited
number of patients, that induced sputum could successfully be
used for immunological diagnosis of TB using purified protein
derivative (PPD)-driven cells in a flow cytometric or ELISPOT
assay [7]. However, the ELISPOT assay which can be interpreted
using a magnifying lens and with minimal training, obviates the
need for technical competence in flow cytometry and costly
instrumentation such as a flow cytometer, making it more
appealing for use in a developing world setting. Moreover, they
studied PPD-associated responses which are non-specific and
detectable even in patients with LTBI. By contrast RD-1 specific
responses in the lung are highly specific even in high burden
countries where the prevalence of LTBI is over 50% [14,16].
Breen et al. produced evaluable test results in all 9 study patients in
whom ELISPOT was performed and total cell yield from induced
sputum samples were almost 6 times greater than those found in
our study. How do we explain these results? We used unselected
and consecutively recruited patients, a different population group,
and different sputum processing methodology. Several other
factors including disease extent, the small number of patients
evaluated by ELISPOT in the Breen study, the duration of sputum
induction and volume of hypertonic saline used, and malnutrition
and hence attenuated immune responses, may explain the
discordant results.
The key drawback of the ELISPOT assay when using cells from
induced sputum was the high proportion (89%) of inconclusive
results. Insufficient cell yield (31%) was the most common reason
for non-evaluable assays. This is not surprising as sputum
Table 2. T-SPOTH.TB assay outcomes and reasons for inconclusive test results in the validation phase.
Validation phase (n =68)+ Test outcomes/reasons for test failures Definite and Probable TB (n =20)+ Non TB *(n=48)
Sputum induction-related factors (n = 39)
1. Inadequate volume of sputum 1 7
2. Failure to homogenise sputum 1 6
3. Insufficient cells 6 18
T-SPOTH.TB related factors (n = 20)
1. Excessive debris (high background) 1 5
2. Positive control failed 1 10
3. Negative control failed 2 1
Valid T-SPOTH.TB result (n = 8)
1. Positive 7# 0
2. Negative 0 1
*The ‘non-TB’ group included i) 29 TB suspects classified as non TB after follow-up and ii) non TB controls patients with alternative respiratory diseases (e.g. interstitial
lung disease).
#6 positive T-SPOTH.TB from definite TB patients and 1 positive T-SPOTH.TB from probable TB patient.
+1 sample rejected due to laboratory labeling error.
doi:10.1371/journal.pone.0010389.t002
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induction samples the large airways rather than the alveolar spaces
where the majority of the mononuclear cells reside. The low
cellular yield is exacerbated by the variable though low proportion
of lymphocytes in pulmonary samples. Increasing the numbers of
cells per well is unlikely to have helped as demonstrated by the
cell-cytokine response curves (Figure 2). We ensured maximal
sample yield through using at least 20 ml of hypertonic saline and
nebulising for at least 15 minutes. The volume and number of
mononuclear cells isolated from the induced sputum samples in
our study was less in females, an association previously reported
[17] but did not correlate with age or HIV positivity. Therefore,
neither obtaining a larger sample volume, nor exposing the patient
to sputum induction for longer, is likely to overcome the problem
of insufficient cells. Furthermore, cell viability was greater than
90% in all samples processed and consequently this factor is
unlikely to have contributed to the poor test outcomes.
Figure 3. AIDH ELISPOT reader images of T-SPOTH.TB wells demonstrating. (A) positive control, (B) valid negative control, (C) positive ESAT-
6 well, (D) high background discoloration and (E,F) artefacts from non-specific debris and mucus.
doi:10.1371/journal.pone.0010389.g003
Table 3. Characteristics of the 8/73 (11%) interpretable T-SPOTH.TB assays.
Spot forming units/106cells SI smear/culture
T-SPOTH.TB result Final diagnosis ESAT-6 CFP-10
Positive
control*
Negative
control* AFB smear MGIT culture
positive Definite TB 120 not done# 100 40 positive positive
positive Definite TB 176 not done# 64 40 positive positive
positive Definite TB 160 not done# 80 20 positive positive
positive Definite TB 28 .250 .250 0 negative positive
positive Definite TB+ 0 .250 .250 0 negative negative
positive Definite TB+ .250 0 60 0 negative negative
positive Probable TB 72 64 .250 12 negative negative
negative Non TB 0 0 40 0 not done$ not done$
Median 96 64 90 0
IQR 21/164 0/250 63/250 0/25
*As per the manufacturer’s guidelines, an assay was considered valid if the number of SFU’s/106cells in the negative control well was twice that of the positive control
well. A value of .250SFU’s/106cells was selected as the cut-off positive value. ESAT-6 = Early Secretory Antigen Target-6. CFP-10 = Culture Filtrate Protein-10.
SI = Induced sputum sample.
#Insufficient cells to plate both wells.
+Patients were found to be culture positive on other biological samples and therefore classified as definite TB.
$Asymptomatic control patient with COPD and normal chest x-ray (sputum smear and culture was not indicate.
doi:10.1371/journal.pone.0010389.t003
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Other factors accounting for the inconclusive results included
high IFN-c readouts in the negative control well and high
background discoloration of the wells likely related to the high
protein and mucus content of induced sputum. It may be argued
that one or more of these factors could be reduced thereby
improving the diagnostic utility and feasibility. However, we
believe this is unlikely for several reasons. Increasing the length of
mixing time after addition of DTT failed to improve sample
quality. Moreover, previous studies [8,18,19] suggest a high degree
of spontaneous IFN-c release by mononuclear cells, in the absence
of any exogenous stimuli, especially those compartmentalized to
the lungs of patients. Finally, several steps were taken to minimise
cellular and other debris.
A limitation of our study was that concurrent blood and induced
sputum assays were not performed, however, the limited utility
and poor specificity of peripheral blood responses for active TB
have been clearly demonstrated in high burden settings [12]. It is
possible, though unlikely, that population-specific factors may
have played a role and thus our findings require confirmation in
different geographical settings.
In summary, we have confirmed that antigen-specific ELISPOT
responses can be detected using cells from induced sputum for the
diagnosis of TB. However, due to several technical factors the
proportion of inconclusive results is too high to warrant current
clinically utility. Further studies are now required to improve the
assay formats and technologies used so that in the future rapid
immunodiagnosis using cells from induced sputum may be
feasible.
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